To evaluate the efficacy and safety of intracoronary administration of prourokinase via balloon catheter during primary percutaneous coronary interventions (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
lead to myocardial necrosis. [2] [3] [4] Previous report showed that the morbidity and mortality of STEMI patients who have good restoration of epicardial blood flow following PCI remains substantial with 30-day, 1-year, and 5-year all-cause mortality rates of approximately 8%, 11%, and 23%, respectively. 5 Some STEMI patients will suffer severe cardiovascular complications and adverse clinical prognosis even with TIMI 3 blood flow in epicardial coronary artery. It was reported that despite the restoration of a good epicardial flow with PCI, myocardial perfusion at the cellular level remains impaired in nearly 50% of STEMI patients, 6 which may attribute to the embolization of the coronary thrombus into the distal vasculature, producing microvascular plugging, vasospasm, interstitial edema, and cellular injury. It has been estimated that an average of 25 embolic events might occur during primary PCI for STEMI. 7 It is needful to identify effective and safe strategies to improve myocardial perfusion after primary PCI.
Recombinant human prourokinase is a fibrin-specific plasminogen activator that has structural similarities to t-PA but has a different mechanism of action. 8 In this study, we aimed to investigate the efficacy and safety of intracoronary administration of prourokinase on myocardial reperfusion in STEMI patients undergoing primary PCI.
| METHODS
We conducted a single center prospective randomized clinical trial on 
| Patient enrollment
From January 2015 to May 2016, consecutive patients (aged years) presented with ST segment elevation myocardial infarction (STEMI) within 12 h of symptom onset undergoing primary PCI were enrolled. Exclusion criteria were: history of intracranial hemorrhage; ischemic cerebral stroke within 3 months; suspicion of aortic dissection; active hemorrhage or hemorrhagic risk (including menstruation); severe or uncontrolled hypertension (≥180/110 mmHg); severe trauma; major operation within 3 weeks; vascular puncture that could not be controlled by compression; malignant tumor; severe hepatic or renal dysfunction; pregnancy or lactation; allergy to or contraindication of prourokinase; post coronary artery bypass graft status;
participating in other clinical trials simultaneously.
| Study protocol
All patients with STEMI as candidates for primary PCI were given 300 mg aspirin and 180 mg ticagrelor before coronary angiography. By using a computer-generated random-allocation system, patients eligible for the study were randomized into two groups: intracoronary prourokinase (IP) group (n = 118), in which an additional bolus of prourokinase (10 mg diluted in 10 mL of saline within 3 min; Shanghai Tasly Pharmaceutical Co., Ltd.) was administered directly through the balloon catheter to the distal end of the culprit lesion; control group (n = 112), in which saline (10 ml within 3 min) was administered by the same way.
Coronary angiography and PCI were performed via radial or femoral access route using a 6F arterial sheath. After the access, 3000 U of heparin was injected through the sheath. Coronary angiography was performed using a 5F TIG multi-functional angiographic catheter. ECG and invasive blood pressure were continuously monitored during the operation. For PCI, additional heparin (70 U/Kg) was routinely given through arterial sheath, a guiding catheter was deployed at the ostium of coronary artery, and the guidewire was delivered to the distal segment of occlusive coronary artery. A balloon catheter was sent to the lesion and the balloon was inflated. Then the balloon was withdrawn and the balloon membrane was punctured with a needle to get a micropore. The punctured balloon was sent to the distal end of occlusive artery, and prourokinase (10 mg dissolved in 10 mL of saline, and injected within 3 min) or saline (10 mL, injected within 3 min) was gradually injected through the balloon. During the injection, changes of blood pressure and heart rate/rhythm were closely observed. After the injection, coronary angiography was performed, and stent was implanted if there was more than 75% residual stenosis.
After the procedure, all patients were given a maintenance dosage of 100 mg aspirin daily and 90 mg ticagrelor twice a day. Other medications like statins, β-receptor blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), glycoprotein IIb/IIIa inhibitor, unfractionated heparin were applied according to guideline recommendations, if not contraindicated. The patients were given oxygen inhalation after the operation, and standard monitors of blood pressure, ECG, and blood oxygen saturation were applied.
| Angiographic analysis
Coronary angiography of the target lesion was performed before and after primary PCI at the identical projections, which allowed optimal evaluation of the TIMI flow grades of the IRA. Visual assessment was made by two experienced interventional cardiologists blinded to the randomization.
| Biochemical assays and ST-segment resolution
Blood samples were obtained from each patient at 6, 12, 24, and 48 h after the symptom onset and right after the completion of PCI. Serum 
| Follow-up
Follow-up was completed by an interview of patients in cardiac clinic or by telephone conversation with patients every month after discharge, and continued for at least 6 months. MACE including stent thrombosis, recurrent myocardial infarction, congestive heart failure, post-infarction angina pectoris, and cardiac death were recorded at 30-day and 6-month follow-up. Hemorrhagic complications, categorized as major or minor bleeding according to the TIMI criteria, local hematoma, and transfusion were recorded. The diagnosis of congestive heart failure consisted of at least one of the following conditions:
(i) requiring treatment with diuretics; (ii) pulmonary oedema or congestion on chest radiograph without suspicion of a non-cardiac cause; (iii) rales of more than 1/3 up from the lung base (Killip class 2 or higher); (iv) dyspnoea with an oxygen pressure of less than 80 mmHg or oxygen saturation of less than 90% without supplemental oxygen and in the absence of known lung disease.
| Statistical analysis
Before the launch of this study, sample size was calculated. The MACE incidence was assumed to be 20% in control group and 10%
in IP group within 6 months, the values of power (1-β) and significance level α (two sided) were set as 80% and 0.05, it was calculated that 108 subjects were needed for each group. 3 | RESULTS
| Baseline demographic, clinical, and angiographic characteristics
In total 230 enrolled STEMI patients completed this study with 118 patients in IP group and 112 patients in control group. Demographic, clinical, and angiographic characteristics of the subjects at baseline are described in Table 1 . No significant differences were observed between two groups with respect to baseline demographic, clinical, and angiographic characteristics (P > 0.05).
| Enzymatic infarct size and myocardial reperfusion
Infarct size was estimated by cardiac markers including serum CK, CK-MB, and TnI. Peak levels of serum CK, CK-MB, and TnI were significantly lower in the IP group than in the control group (P < 0.05) ( Table 2) . Myocardial reperfusion was estimated by the rates of ST segment resolution, and results showed that in IP group, more patients had complete ST segment resolution (>70%) compared with control group (P < 0.05) ( Table 2) . MCE is an excellent tool for studying regional myocardial perfusion with the potential to visualizing the transmural distribution of MBF which was also used in this study to evaluate the myocardial perfusion after the PCI. Results showed a much higher MBF in IP group compared with control group (P < 0.05), the results of PI, TP, video intensity of peak value (A) and microbubble velocity (β)
were also much better in IP group compared with control group (P < 0.05) ( Table 3 ).
| Cardiac functions
The values of LVEF, LVEDd, and WMSI 1 day, 7 days, and 30 days after PCI were measured to estimate the cardiac functions. There were no significant differences between two groups with respect to LVEF, LVEDd, and WMSI 1 day after PCI (P > 0.05). At Day 7 after the PCI, there were no significant differences between two groups with respect to LVEF and LVEDd, however, WMSI in IP group was much lower than in the control group (P < 0.05). One month after PCI, the values of LVEF, LVEDd, and WMSI were all much better in IP group than in the control group (P < 0.05) ( Table 4) .
| Hemorrhagic complications and MACE during the follow-up
During the follow-up, no intracranial hemorrhage was found in both groups. The numbers of bleeding complications in two groups were listed in Table 5 . There were eight bleeding complications (including 1 TIMI major bleeding event, 7 TIMI minor bleeding events, 5 local hematomas, and 1 transfusion) in IP group and 7 bleeding complications (including 3 TIMI major bleeding event, 4 TIMI minor bleeding events, 6 local hematomas, and 3 transfusion) in control group. All local hematomas occurred in the puncture sites of femoral artery. With respect to the number of TIMI major or minor bleeding complications, no significant differences were observed between the two groups (P > 0.05). At 30 days, there was no difference in MACE rate between the two groups (P > 0.05). At 6-months follow-up, there was a trend that patients in the IP group had a less chance to have MACE, though it was not statistically different (8.5% vs 12.5%, P = 0.434). prourokinase into the remote end of coronary lesion, placement of the catheter just proximal to the lesion would be essential, as drug may be significantly diluted due to the combined effects of pulsatility, vessel wall anomalies, and the multiphasic nature of blood flow. 20 The safety and cost of drug delivery were also important factors we concerned.
However, most of the drugs delivered via guiding catheter will be washed away in systemic circulation or be delivered to unwanted branches, little will reach the target coronary lesion; it is also difficult for suction catheter to deliver and retain adequate amounts of drug to the target lesion due to the large diameter of the catheter; delivery of drugs via microcatheter requires the guide wire to be withdrawn before the delivery and to be repositioned for the PCI after the delivery, which will lead to prolonged operation time and increased complication risks; newly developed infusion balloon may be effective for drug delivery, but the high price limits its wide application. There are some reports in China that intracoronary drug delivery is achieved by modified balloon catheter. Based on these studies, we developed a simple, effective, and low-cost method to deliver prourokinase via a punctured balloon after the inflation of the balloon was finished. After the injection of prourokinase, the balloon was washed with saline to minimize drug residue. 24 Studies have demonstrated that the sensitivity and specificity of qualitative assessment of myocardial perfusion by MCE in patients with acute and chronic ischemic heart disease are comparable with other techniques such as standard echocardiography 25 and SPECT. 26 The unique advantage of this method over others for assessing myocardial perfusion is that it can measure both components of tissue perfusion: MBF velocity (β) and myocardial blood volume (MBV), the latter being denoted by the value A. 27 MBF can be estimated by the product of A and β. During pharmacologic stress, impaired hyperemic flow in the presence of coronary stenosis was associated with decreases in both A and β. MBF reserve decreased in a step-wise manner in mild, moderate, and severe stenosis. 28 Quantitative measure of MCE is also used to assess perfusion defect after AMI or to predict recovery of hibernating myocardium, and results suggested that the best MCE parameter for predicting myocardial functional recovery was Aβ, the index of MBF. 29, 30 In our study, MCE was used to quantitatively evaluate myocardial perfusion at day 7 after prourokinase administration, results showed a significantly higher MBF, myocardial blood volume (A) and MBF velocity (β) in IP group compared with control group, along with other indicators including peak intensity and time to peak, suggesting a better improvement of myocardial perfusion in patients with IP administration.
We assumed that prourokinase administration via balloon to the remote end of lesion during the primary PCI could increase local drug concentration at the thrombotic lesion, exert local thrombolytic effect, and might reduce hemorrhagic risks. However, results showed that there were no significant differences between two groups with respect to bleeding complications. At 6-months follow-up, there was a trend that patients in the IP group had a less chance to have MACE events, though it was not statistically different, suggesting that IP administration during primary PCI may be trend to decrease MACE events for STEMI patients in the long term. The lack of statistical difference in the outcome could probably due to the insufficient sample size. Before the launch of this study, sample size was estimated based on previous studies on early coronary intervention after thrombolysis in AMI (such as NORDISTEMI study, 31 Routine Early Angioplasty after Fibrinolysis for Acute
Myocardial Infarction, 32 Long-term follow-up of early versus delayed invasive approach after fibrinolysis in acute myocardial infarction 33 ) combined with experiences in our center, the MACE incidence was assumed to be 20% in control group and 10% in prourokinase group at 6 months. However, the actual results proved that it was an overoptimistic estimation as out of the 20% expected events at 6 months in the control group only 12.5% occurred. Studies with larger sample size are needed to verify the results, and our work may provide some experiences on sample size estimation and power calculation.
Besides the insufficient sample size, there are other limitations that can be improved in any future study. In our work, all the patients in the IP group were given 10 mg prourokinase via the balloon catheter during primary PCI which could significantly improve myocardial reperfusion. Take into consideration that different dosage and administration route of the drug may influence the efficacy and safety, future studies are needed to explore the most ideal dosage and route of prourokinase administration.
In conclusion, IP administration can improve myocardial perfusion in acute STEMI patients undergoing primary PCI without increasing incidence of hemorrhagic complications and MACE events.
